局部鼻腔治疗对成人阻塞性睡眠呼吸暂停严重程度的疗效:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项研究,评估局部鼻腔治疗(减充血剂、皮质类固醇、抗组胺药)对成人OSA患者的影响。定性分析显示所有研究均呈现OSA客观与主观指标改善趋势,但5项研究的荟萃分析未发现AHI显著变化(p>0.05)。局部鼻腔治疗可能改善最低血氧饱和度、ODI、RDI及生活质量,过敏患者可能获益更多。
要点
- 局部鼻腔治疗可能改善OSA患者最低血氧饱和度、ODI、RDI及生活质量。
- 荟萃分析未发现局部鼻腔治疗显著降低AHI(p>0.05)。
- 过敏患者较非过敏患者的OSA指标可能改善更明显。
核心结论
- 局部鼻腔治疗可能改善最低血氧饱和度、ODI、RDI及主观/生活质量指标。
- 过敏患者较非过敏患者的OSA指标可能改善更多。
- 未来需研究准确确定局部鼻腔治疗的疗效。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Ovid MEDLINE和Cochrane Central(2001年1月至2019年7月)。
- 纳入标准为英文研究,含局部鼻腔治疗用于成人(≥18岁)OSA(AHI≥5)的原始数据。
- 排除病例报告、无结局指标的研究及同时接受非局部鼻腔治疗的研究。
- 共识别2180篇摘要,最终8项研究符合纳入标准。
主要发现
- 干预措施包括减充血剂(8项中4项)、皮质类固醇(8项中3项)和抗组胺药(8项中1项)。
- 结局指标包括AHI(8项中8项)、RDI(1项)、ODI(3项)、最低SaO2(4项)、鼻阻力(4项)、内镜鼻窦手术(4项)及标准化鼻结膜炎生活质量问卷评分(1项)。
- 定性分析显示所有研究均呈现OSA客观和主观指标改善趋势,但显著性因研究而异。
- 5项研究的荟萃分析显示局部鼻腔治疗未显著改变AHI(p>0.05)。
临床怎么用
- 对于合并鼻部疾病的成人OSA患者,局部鼻腔治疗可能作为辅助手段改善血氧指标和生活质量。
- 不应期望局部鼻腔治疗显著降低AHI,需结合其他OSA治疗方式。
- 过敏患者可能从局部鼻腔治疗中获得更多OSA相关指标改善。
局限性
- 纳入研究数量少(仅8项),且干预措施和结局指标异质性较大。
- 仅纳入英文研究,可能存在语言偏倚。
- 部分结局指标仅由少数研究报道,证据力度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nasal obstruction is a common complaint in patients with sleep-disordered breathing and obstructive sleep apnea (OSA). Although topical nasal treatments (TNTs) have been shown to reduce nasal resistance and improve nasal obstruction, there is conflicting evidence regarding the role of TNTs in adult OSA. In this systematic review and meta-analysis we aim to evaluate the role of TNTs in adults with OSA. Data sources used included PubMed, Ovid MEDLINE, and Cochrane Central, from January 2001 to July 2019. METHODS: Inclusion criteria were English-language studies containing original data on TNTs in adults (≥18 years) with OSA (apnea-hypopnea index [AHI] ≥5). Exclusion criteria were case reports, studies without outcome measures, and concurrent non-TNT treatment for OSA. Two investigators independently reviewed all articles and performed quality assessment using validated tools. Meta-analysis and quality assessment were performed. RESULTS: Of the 2180 abstracts identified, 8 studies met inclusion criteria. TNTs included decongestants (4 of 8 studies), corticosteroids (3 of 8), and antihistamines (1 of 8). Outcome measures included AHI (8 of 8), respiratory distress index (RDI; 1 of 8), oxygen-desaturation index (ODI; 3 of 8), minimum SaO2 (MinSaO2 ; 4 of 8), nasal resistance (4 of 8), endoscopic sinus surgery (4 of 8 studies) and standardized rhinoconjunctivitis quality of life questionnaire scores (1 of 8 studies). Qualitatively, all studies showed trends toward improving objective and subjective measures of OSA, although the significance of these improvements varied across studies. A meta-analysis was performed in 5 studies, but TNTs did not reveal a significant change in AHI (p > 0.05). CONCLUSION: TNTs may improve minimum oxygen saturation, ODI, RDI, and subjective/quality-of-life measures. Allergic patients may have more improvement in OSA measures compared with nonallergic patients. Future studies are indicated to accurately determine the efficacy of TNTs.
引用
- Nguyen DK, Liang J, Durr M, et al. Topical nasal treatment efficacy on adult obstructive sleep apnea severity: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2020. PMID: 32713164. doi:10.1002/alr.22658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。